GDRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
GoodRx Holdings Inc (GDRX) is not a good buy for a beginner investor with a long-term strategy at this time. The company faces significant challenges, including declining prescription discount revenue, hedge fund selling, and negative analyst sentiment. While there are some positive developments, such as growth in Pharma Direct revenue and new subscription adoption, these are overshadowed by broader financial and operational struggles. The technical indicators and options data do not suggest a strong buying opportunity, and the absence of Intellectia Proprietary Trading Signals further supports a cautious approach.
The MACD is slightly positive but contracting, indicating weak momentum. RSI is neutral at 31.208, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 2.015), but the pre-market drop of -19.18% suggests bearish sentiment. Overall, the technical indicators do not support a strong buy signal.
Pharma Direct revenue grew 41% YoY, indicating successful strategic shifts.
Strong early adoption of condition-specific subscriptions, particularly in the weight loss sector.
Declining prescription discount revenue, which accounts for 70% of the company's revenue.
Hedge funds are selling, with a 1160% increase in selling activity over the last quarter.
Negative analyst sentiment, with multiple downgrades and price target reductions.
Financial performance shows declining revenue and net income in Q4 2025.
In Q4 2025, revenue dropped by -1.91% YoY to $194.8 million, and net income fell by -19.51% YoY to $5.43 million. EPS remained flat at 0.02, while gross margin decreased by -6.04% YoY to 79.15%. The company anticipates 2026 revenue between $750 million and $780 million, reflecting ongoing pressure on its core prescription transaction revenue.
Analyst sentiment is largely negative. Recent downgrades include Jefferies lowering its rating to Hold with a price target of $2.75, and BofA maintaining an Underperform rating with a price target of $2.60. While some analysts remain cautiously optimistic, the majority highlight challenges such as declining volumes, pricing pressure, and slow recovery in the prescription discount segment.
